Q-omics provides the consensus-scored MTCO2P8 profile across patient tissues and cancer cell-line models. MTCO2P8 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTCO2P8 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MTCO2P8 RNA expression shows 9,156 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, BRCA, and THYM as cancer lineages where MTCO2P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO2P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO2P8 survival associations across molecular data types. MTCO2P8 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO2P8 RNA expression–survival associations across cancer types. High MTCO2P8 expression shows unfavorable associations in MESO, HNSC, BRCA, DLBC and THCA, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for MTCO2P8 RNA expression.
This table summarizes MTCO2P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO2P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO2P8 shows higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher MTCO2P8 RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p = .008).
This table shows molecular features associated with MTCO2P8 in patient tissues and cancer cell lines. In patient samples, MTCO2P8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
